

FORM 7

MONTHLY PROGRESS REPORT

For June 2020

Name of Listed Issuer: Liberty Health Sciences Inc. (the "Issuer" or "Company").

Trading Symbol: LHS

Number of Outstanding Listed Securities: 346,090,635 common shares

Date: July 7, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On June 2nd, the company announced it will open its 24th dispensary in West Palm Beach as it continues to expand its retail footprint across Florida. Liberty's newest dispensary is located at 1540 Palm Beach Lakes Blvd., Suite: 170, West Palm Beach, FL. 33401 and will serve a local population of more than 100,000. The 2,000 square foot dispensary boasts a modern display and retail area, two private consultation rooms and two waiting areas. The store will be open Monday through Friday, 10 a.m. to 7 p.m., Saturday, 10 a.m. to 5 p.m., and Sunday, 12 p.m. to 5 p.m. As with all Liberty locations, locally inspired wall-art will be featured throughout the store on a rotating basis. This is the company's second store location in Palm Beach County. The dispensary will offer a wide variety of medical and wellness products in multiple delivery options, including vaporizer pens, tinctures, oral sprays, flower, topical creams, concentrates and distillates, and time released transdermal patches. Liberty plans to open an additional 10 new dispensaries by the end of this year.

On June 10th, the company announced it plans to open the doors of its 25th dispensary in Stuart, Florida, subject to approval from the Florida Department of Health. Liberty's newest 5,000 square foot dispensary is located at 3323 SE Federal Highway Stuart, FL. 34997 and provides a spacious display and retail area, two private consultation rooms and one large waiting. The store will be open Monday through Friday, 10 a.m. to 7 p.m., Saturday, 10 a.m. to 5 p.m., and Sunday, 12 p.m. to 5 p.m. As with all Liberty locations, locally inspired wall-art will be featured throughout the store on a rotating basis.

On June 26th, the company announced its financial results for the fiscal year 2020 ending February 29, 2020. Consolidated net sales for fiscal year-end February 29, 2020 were \$50,075,579, compared with \$10,002,538 for fiscal year-end February 28, 2019. The company's aggregate operating expenses decreased from \$25,588,038 for fiscal year 2019 to \$25,184,000 for fiscal year 2020 ending February 29, 2020. The Company recorded net income for the fiscal year-end February 29, 2020 of \$22,266,322, which includes the gain on the sale of a property of \$14,266,807, compared with a net loss of \$22,293,815 for the fiscal year ended February 28, 2019. The significant year-over-year increase in revenue was driven by the Company's introduction of more than 200 new

products, the opening of new dispensaries, expanded delivery infrastructure, as well as an upsurge in same store sales volume and an increase in registered patient base for Medical Marijuana Use in Florida.

2. Provide a general overview and discussion of the activities of management.

In Florida, in addition to initiating production expansion activities at its Liberty 360° Innovation Campus in Gainesville, management continues to seek and open potential dispensary sites.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of June.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of June.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On June 5th, the company announced it entered into a licensing agreement with California-based DomPen www.dompen.co, one of the cannabis industry's leading disposable vaporizer pens and cartridge companies. The agreement allows Liberty to sell DomPen products in all its Florida locations by the second week of June. DomPen was founded in Los Angeles in 2015 and focuses on developing new cannabinoids and customized vaporization hardware. The company is known for its innovative manufacturing and distribution capabilities along with its standardized quality control methods to improve product safety, consistency, and predictability.

On June 19th, the company announced it entered into a licensing agreement with licensed California adult use and medicinal cannabis company HONEY®, one of California's largest full service companies, to supply all of Liberty's dispensaries with the company's full assortment of branded products. In 2012 HONEY® revolutionized the cannabis industry by becoming the first producer in the world to market distilled cannabis oil in vape cartridges. Today, they provide authentic, full spectrum oil in vape cartridges, applicators, and caps to legal dispensaries and delivery services.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report in the month of June.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report in the month of June.

8. Describe the acquisition of new customers or loss of customers.

The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients and as the Company expands its footprint in the state. The Florida market has also reacted positively to Liberty's whole flower products and continues to assist to expand Liberty's customer base.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report in the month of June.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company continues to add personnel in the areas of patient care and processing in the Florida operations and dispensaries with the expected opening of additional dispensaries over the next 30-60 days.

There were no significant terminations or lay-offs in the month of June.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of June.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month June.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No new debt to report for the month of June.

14. Provide details of any securities issued and options or warrants granted.

None to report in the month June.

15. Provide details of any loans to or by Related Persons.
None to report in the month of June.
16. Provide details of any changes in directors, officers or committee members.
None to report in the month June.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None to report in the month June.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated July 7, 2020.

Sheri Cholodofsky
Name of Director or Senior Officer

"Sheri Cholodofsky"
Signature

CFO
Official Capacity

<i>Issuer Details</i> Name of Issuer Liberty Health Sciences Inc.	For Month End June 30, 2020	Date of Report YY/MM/DD 20/07/07
Issuer Address 78 Gwendolen Crescent		
City/Province/Postal Code Toronto, ON, Canada M2N 2L7	Issuer Fax No.	Issuer Telephone No.
Contact Name Sheri Cholodofsky	Contact Position CFO	Contact Telephone 833 254 4877
Contact Email Address ir@libertyhealthsciences.com	Web Site Address https://libertyhealthsciences.com/	